• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低分化甲状腺癌与经典型乳头状甲状腺癌的临床特征比较。

Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas.

作者信息

Lin Jen-Der, Chao Tzu-Chieh, Hsueh Chuen

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taiwan, ROC.

出版信息

Clin Endocrinol (Oxf). 2007 Feb;66(2):224-8. doi: 10.1111/j.1365-2265.2006.02712.x.

DOI:10.1111/j.1365-2265.2006.02712.x
PMID:17223992
Abstract

OBJECTIVE

The aim of this study was to compare the clinical presentation and prognosis of poorly differentiated thyroid carcinoma (PDTC) with those of classical papillary thyroid carcinoma (PTC) to identify the appropriate surgical modalities for use in conjunction with radioactive iodide ((131)I) therapy and external radiotherapy for treating PDTC.

DESIGN

Sixty-seven PDTC patients (mean age 50.3 +/- 18.1 years, range 14-82 years) underwent surgery at the Chang Gung Medical Centre (CGMC), Linkou. To compare clinical presentations and treatment outcomes, 134 age- and gender-matched patients with classical PTC were selected randomly from the patient database at CGMC.

RESULTS

Of the 67 PDTC patients, 53 underwent near-total thyroidectomy. Following surgery, 45 were administered (131)I for remnant ablation and treatment of distant metastatic disease. Forty-one of the 67 (61.2%) patients with PDTC and 26/134 (19.4%) with classical PTC failed to achieve disease-free status. Twenty-four of the 67 (34.3%) PDTC patients eventually died of thyroid cancer after a mean follow-up of 5.9 +/- 0.6 years. Age and TNM staging at surgery were significant indicators of PDTC patient survival and mortality.

CONCLUSIONS

As the prognosis for PDTC patients is poorer than that for classical PTC patients, (131)I treatment following surgery is useful. To improve the survival rate, early diagnosis is crucial for PDTC.

摘要

目的

本研究旨在比较低分化甲状腺癌(PDTC)与经典乳头状甲状腺癌(PTC)的临床表现和预后,以确定与放射性碘((131)I)治疗及外照射放疗联合使用的适合治疗PDTC的手术方式。

设计

67例PDTC患者(平均年龄50.3±18.1岁,范围14 - 82岁)在林口长庚医学中心(CGMC)接受手术。为比较临床表现和治疗结果,从CGMC患者数据库中随机选取134例年龄和性别匹配的经典PTC患者。

结果

67例PDTC患者中,53例行近全甲状腺切除术。术后,45例接受(131)I治疗以消融残余甲状腺组织及治疗远处转移疾病。67例PDTC患者中有41例(61.2%)、134例经典PTC患者中有26例(19.4%)未达到无病状态。67例PDTC患者中有24例(34.3%)在平均随访5.9±0.6年后最终死于甲状腺癌。手术时的年龄和TNM分期是PDTC患者生存和死亡的重要指标。

结论

由于PDTC患者的预后比经典PTC患者差,术后(131)I治疗是有用的。为提高生存率,早期诊断对PDTC至关重要。

相似文献

1
Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas.低分化甲状腺癌与经典型乳头状甲状腺癌的临床特征比较。
Clin Endocrinol (Oxf). 2007 Feb;66(2):224-8. doi: 10.1111/j.1365-2265.2006.02712.x.
2
Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.肿瘤分期超过T1N0M0的甲状腺乳头状癌的治疗结果
Radiother Oncol. 2008 Oct;89(1):97-104. doi: 10.1016/j.radonc.2008.05.011. Epub 2008 Jun 3.
3
High recurrent rate of multicentric papillary thyroid carcinoma.多中心性乳头状甲状腺癌的高复发率。
Ann Surg Oncol. 2009 Sep;16(9):2609-16. doi: 10.1245/s10434-009-0565-7. Epub 2009 Jun 16.
4
Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.在同一机构接受治疗和随访的高分化甲状腺癌患者的预后因素。
Ann Ital Chir. 2006 Mar-Apr;77(2):107-13.
5
Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas.甲状腺乳头状癌滤泡状变体的临床表现及手术治疗结果
Jpn J Clin Oncol. 2006 Nov;36(11):688-93. doi: 10.1093/jjco/hyl093. Epub 2006 Sep 25.
6
Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.首次放射性碘治疗后复发的甲状腺乳头状癌患者的临床结局
Cancer. 1996 Aug 1;78(3):493-501. doi: 10.1002/(SICI)1097-0142(19960801)78:3<493::AID-CNCR17>3.0.CO;2-U.
7
Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.基于有丝分裂和坏死定义的低分化甲状腺癌:58例患者的临床病理研究
Cancer. 2006 Mar 15;106(6):1286-95. doi: 10.1002/cncr.21739.
8
Treatment for microcarcinoma of the thyroid--clinical experience.甲状腺微小癌的治疗——临床经验
Clin Nucl Med. 2007 Apr;32(4):279-81. doi: 10.1097/01.rlu.0000257272.90126.3d.
9
Differentiated thyroid cancer in a Swedish county--long-term results and quality of life.在瑞典的一个县中分化型甲状腺癌——长期结果和生活质量。
Acta Oncol. 2010 May;49(4):454-9. doi: 10.3109/02841860903544600.
10
Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.全甲状腺切除术后对侧甲状腺乳头状癌对放射性碘治疗后的复发或生存无影响。
Surgery. 2006 Dec;140(6):1043-7; discussion 1047-9. doi: 10.1016/j.surg.2006.08.007. Epub 2006 Nov 1.

引用本文的文献

1
Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis.低分化甲状腺癌的预后:系统评价和荟萃分析。
Endocrinol Metab (Seoul). 2024 Aug;39(4):590-602. doi: 10.3803/EnM.2024.1927. Epub 2024 Jun 27.
2
Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.未分化甲状腺癌:概念争议与临床影响。
Virchows Arch. 2024 May;484(5):733-742. doi: 10.1007/s00428-024-03752-5. Epub 2024 Feb 24.
3
Poorly differentiated thyroid carcinoma: a clinician's perspective.低分化甲状腺癌:临床医生视角
Eur Thyroid J. 2022 Mar 24;11(2):e220021. doi: 10.1530/ETJ-22-0021.
4
SYT12 is a novel oncogene that promotes thyroid carcinoma progression and metastasis.SYT12是一种促进甲状腺癌进展和转移的新型癌基因。
J Cancer. 2021 Sep 27;12(22):6851-6860. doi: 10.7150/jca.62555. eCollection 2021.
5
PSD3 is an oncogene that promotes proliferation, migration, invasion, and G1/S transition while inhibits apoptotic in papillary thyroid cancer.PSD3是一种癌基因,它在甲状腺乳头状癌中促进细胞增殖、迁移、侵袭以及G1/S期转换,同时抑制细胞凋亡。
J Cancer. 2021 Jul 13;12(18):5413-5422. doi: 10.7150/jca.60885. eCollection 2021.
6
Variable response to radioactive iodine treatment in poorly differentiated thyroid carcinoma.低分化甲状腺癌对放射性碘治疗的反应各异。
Gland Surg. 2019 Dec;8(6):589-590. doi: 10.21037/gs.2019.10.14.
7
Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.由 STRN-ALK 表达和 p53 缺失驱动的甲状腺癌进展和去分化的小鼠模型:两种低分化癌存在的证据。
Thyroid. 2019 Oct;29(10):1425-1437. doi: 10.1089/thy.2019.0284. Epub 2019 Aug 16.
8
Thyroglobulin "Nonsecretor" Metastatic Poorly Differentiated Thyroid Carcinoma with Noniodine Concentrating Disease and Aggressive Clinical Course: A Clinical Case Series.甲状腺球蛋白“非分泌型”转移性低分化甲状腺癌伴非碘聚集性疾病及侵袭性临床病程:临床病例系列
Indian J Nucl Med. 2018 Jul-Sep;33(3):218-223. doi: 10.4103/ijnm.IJNM_45_18.
9
Poorly Differentiated Thyroid Carcinoma: 10-Year Experience in a Southeast Asian Population.低分化甲状腺癌:东南亚人群的10年经验
Endocrinol Metab (Seoul). 2017 Jun;32(2):288-295. doi: 10.3803/EnM.2017.32.2.288.
10
Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study.高分化甲状腺癌预后因素与临床结局的关联:一项为期10年的回顾性随访研究。
Oncol Lett. 2015 Sep;10(3):1749-1754. doi: 10.3892/ol.2015.3416. Epub 2015 Jun 24.